• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Asensus Surgical Inc.

    8/22/24 9:30:38 AM ET
    $ASXC
    Medical/Dental Instruments
    Health Care
    Get the next $ASXC alert in real time by email
    S-8 POS 1 asxc20240820o_s8pos.htm FORM S-8 POS asxc20240820o_s8pos.htm

    As filed with the Securities and Exchange Commission on August 22, 2024

     

    Registration No. 333-272523

    Registration No. 333-258160

    Registration No. 333-249895

    Registration No. 333-239018

    Registration No. 333-231078

    Registration No. 333-225231

    Registration No. 333-219111

    Registration No. 333-211972

    Registration No. 333-203950

    Registration No. 333-197908

    Registration No. 333-193234

    Registration No. 333-191011

    Registration No. 333-190184

    Registration No. 333-161291

     


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-272523

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-258160

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-249895

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-239018

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-231078

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-225231

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-219111

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-211972

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-203950

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-197908

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-193234

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-191011

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-190184

    POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT NO. 333-161291

     

    UNDER

    THE SECURITIES ACT OF 1933

     

    ASENSUS SURGICAL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    11-2962080

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Address of principal executive offices and zip code)

     

     

     

     

    Asensus Surgical, Inc. (fka TransEnterix, Inc., fka SafeStich Medical, Inc.) Amended and Restated Incentive Compensation Plan

    Employment Inducement Restrict Stock Unit Award Agreement

    Employment Inducement Performance Restrict Stock Award Agreement

    Employment Inducement Stock Option Agreement

    Restricted Stock Award Agreement, dated as of October 2, 2013

    2006 Incentive Compensation Plan, as amended

    (Full Title of Plan)

     

    Shameze Rampertab

    Executive Vice President and Chief Financial Officer

    1 TW Alexander Drive, Suite 160

    Durham, NC 27703

    (919) 765-8400

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Mary J. Mullany, Esquire

    Ballard Spahr LLP

    1735 Market Street, 51st Floor

    Philadelphia, PA 19103

    (215) 864-8631

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This post-effective amendment filed by Asensus Surgical, Inc. (the “Company”) deregisters all securities that remain unsold under the following registration statements on Form S-8 (the “Registration Statements”) filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”):

     

     

    ●

    Registration No. 333-272523, registering 22,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”);

     

    ●

    Registration No. 333-258160, registering 22,000,000  shares of Common Stock;

     

    ●

    Registration No. 333-249895, registering 200,000  shares of Common Stock;

     

    ●

    Registration No. 333-239018, registering 6,000,000  shares of Common Stock;

     

    ●

    Registration No. 333-231078, registering 12,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-225231, registering 15,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-219111, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-211972, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-203950, registering 7,000,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-197908, registering 200,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-193234, registering 19,700,000  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-191011, registering 15,680,775  shares of Common Stock (not reverse stock split effected);

     

    ●

    Registration No. 333-190184, registering 3,000,000  shares of Common Stock (not reverse stock split effected); and

     

    ●

    Registration No. 333-161291, registering 2,000,000  shares of Common Stock (not reverse stock split effected).

     

    On August 22, 2024 (the Effective Time”) the Company completed the merger contemplated by the Agreement and Plan of Merger, dated as of June 6, 2024 (the “Merger Agreement”), by and among the Company, KARL STORZ Endoscopy-America, Inc., a California corporation (“Parent”), and Karl Storz California Inc., a California corporation and a wholly owned Subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent (the “Merger”). Upon consummation of the Merger, at the Effective Time, each outstanding share of Common Stock of the Company (other than shares owned by the Company, Parent or Merger Sub (which shares were canceled)) was automatically converted into the right to receive $0.35 in cash, without interest. In connection with the completion of the Merger and related transactions contemplated by the Merger Agreement, the offerings pursuant to the above-referenced Registration Statements have been terminated.

     

    In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities that had been registered for issuance but remain unsold at the termination of the offerings, this post-effective amendment removes from registration any and all securities that were registered under the Registration Statements and remain unsold at the termination of the offerings. Each of the Registration Statements is hereby amended, as appropriate, to reflect the deregistration of such securities.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on the 22nd day of August 2024.

     

      Asensus Surgical, Inc.  
           
      By: /s/         Shameze Rampertab  
      Shameze Rampertab, Executive Vice President and Chief Financial Officer  

     

    Note: No other person is required to sign this Post-Effective Amendment to the Registration Statements on Form S-8 in reliance upon Rule 478 under the Securities Act of 1933.

     

     
    Get the next $ASXC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASXC

    DatePrice TargetRatingAnalyst
    11/16/2023Overweight → Neutral
    Cantor Fitzgerald
    9/8/2022$1.50Overweight
    Cantor Fitzgerald
    9/8/2022$1.50Buy
    Stifel
    More analyst ratings

    $ASXC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Asensus Surgical Announces Closing of Acquisition by KARL STORZ

      RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub

      8/22/24 8:58:30 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Reports Operating and Financial Results for the Second Quarter 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,

      8/13/24 4:05:00 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

      8/8/24 6:50:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Financials

    Live finance-specific insights

    See more
    • Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately

      8/8/24 6:50:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

      RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audi

      5/7/24 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024

      RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To

      3/15/24 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Asensus Surgical Inc.

      SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      7/15/24 5:33:42 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Asensus Surgical Inc. (Amendment)

      SC 13G/A - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      1/20/23 9:38:51 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Asensus Surgical Inc.

      SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)

      2/10/22 12:45:15 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Leadership Updates

    Live Leadership Updates

    See more
    • Asensus Surgical Announces the Appointment of Two New Board Members

      Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately. "We are delighted to welcome two accomplished industry veterans to our Board of Directors, each of whom bring highly relevant and unique skills to the organization that complement our current leadership team in an impactful way," said Paul LaViolette, Chairman of the Board of Asensus Surgical. "Liz has a tremendous track record of bringing innovative healthcare t

      7/26/21 6:55:00 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

      BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and

      5/28/21 8:00:00 AM ET
      $OPK
      $ASXC
      $GPX
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Other Consumer Services

    $ASXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kwo Elizabeth returned 117,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:13:46 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Director Hobert Kevin J returned 54,201 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:12:57 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Director Pfenniger Richard C Jr returned 189,417 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      8/22/24 9:12:10 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Asensus Surgical Inc.

      15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      9/3/24 7:00:04 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Asensus Surgical Inc.

      EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      8/27/24 12:15:07 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Asensus Surgical Inc.

      EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)

      8/27/24 12:15:04 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Asensus Surgical downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral

      11/16/23 7:11:26 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Asensus Surgical with a new price target

      Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50

      9/8/22 7:20:54 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Asensus Surgical with a new price target

      Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50

      9/8/22 7:19:37 AM ET
      $ASXC
      Medical/Dental Instruments
      Health Care

    $ASXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Starling William N Jr bought $5,078 worth of shares (18,134 units at $0.28) and sold $5,078 worth of shares (18,134 units at $0.28) (SEC Form 4)

      4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)

      12/18/23 6:26:08 PM ET
      $ASXC
      Medical/Dental Instruments
      Health Care